Meeting
2020 ASCO Virtual Scientific Program
A phase II open-label, single-center, nonrandomized trial of Y90-radioembolization in combination with nivolumab in Asian patients with advanced hepatocellular carcinoma: CA 209-678.
Authors
Wai Meng David Tai
National Cancer Center Singapore, Singapore, Singapore
Wai Meng David Tai , Kelvin Siu Hoong Loke , Apoorva Gogna , Sze Huey Tan , David Chee Eng Ng , Tiffany Priyanthi Hennedige , Farah Irani , Joycelyn Jie Xin Lee , Chow Wei Too , Matthew C.H. Ng , Chee Kian Tham , Justina Yick Ching Lam , Si-Lin Koo , Alexander Chung , Han Chong Toh , Choon Hua Thng , Kiat Hon Lim , Joe Poh Sheng Yeong , Chung Yip Chan , Su Pin Choo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT03033446
Citation
J Clin Oncol 38: 2020 (suppl; abstr 4590)
DOI
10.1200/JCO.2020.38.15_suppl.4590
Abstract #
4590
Poster Bd #
198
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Sintilimab plus lenvatinib as conversion therapy in patients with unresectable locally intermediate to advanced hepatocellular carcinoma: A single-arm, single-center, open-label, phase 2 study.
First Author: Lijun Wang
Poster
2020 ASCO Virtual Scientific Program
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01).
First Author: Kohei Shitara
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of TACE combined with anlotinib compared with TACE alone among patients with intermediate or advanced hepatocellular carcinoma (HCC): A randomized, controlled, phase II clinical study.
First Author: Hui Zeng
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of envafolimab plus lenvatinib combined with TACE in unresectable hepatocellular carcinoma: An open-label, single-arm, phase 2 study—The CISLD-12 study.
First Author: Tingbo Liang